Table 4.
Change in laboratory test after 16weeks.
| Baseline | After 16 Weeks | p-Value ** | |
|---|---|---|---|
| Total group | |||
| Serum total IgE (min–max) | 316.5 (11.0–5000.0) | 304.0 (6.0–2648.0) | |
| Median percent change ± IQR * in total IgE |
3.48 ± 117.64 **** | 0.981 | |
| Serum TEC (min–max) | 672.0 (57.0–6066.0) | 600.0 (82.0–6536.0) | |
| Median percent change ± IQR * in TEC | 14.09 ± 84.80 **** | 0.954 | |
| Serum LDH (min–max) | 252.0 (130.0–491.0) | 218.0 (132.0–385.0) | |
| Median percent change ± IQR * in LDH | 24.14 ± 21.85 | 0.010 | |
| Dupilumab-only group *** | |||
| Serum total Ig E (min–max) | 368.0 (11.0–5000.0) | 364.0 (52.0–2648.0) | |
| Median percent change ± IQR * in total IgE | 5.01 ± 105.66 **** | 0.636 | |
| Serum TEC (min–max) | 563.0 (57.0–6066.0) | 588.0 (82.0–3840.0) | |
| Median percent change ± IQR * in TEC |
13.51 ± 77.75 **** | 0.860 | |
| Serum LDH (min–max) | 242.0 (130.0–392.0) | 215.0 (132.0–348.0) | |
| Median percent change ± IQR * in LDH | 21.27 ± 27.83 **** | 0.098 | |
* The median percent change ± IQR was defined as the median of the percentage of change from baseline to 16 weeks. ** p-value calculated using the Wilcoxon signed-rank test. *** Dupilumab-only group without concomitant treatment. **** Negative value means an increase compared with baseline. IgE: immunoglubulin E; TEC: total eosinophil count; LDH: lactate dehydrogenase; IQR: interquartile range.